90 related articles for article (PubMed ID: 8819514)
1. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
Aceto MD; Scates SM; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1996 Sep; 278(3):1290-5. PubMed ID: 8819514
[TBL] [Abstract][Full Text] [Related]
2. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
Aceto MD; Scates SM; Lowe JA; Martin BR
Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
[TBL] [Abstract][Full Text] [Related]
4. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
5. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
Costa B; Giagnoni G; Colleoni M
Psychopharmacology (Berl); 2000 Apr; 149(2):121-8. PubMed ID: 10805606
[TBL] [Abstract][Full Text] [Related]
6. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
7. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
8. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
10. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.
Hutcheson DM; Tzavara ET; Smadja C; Valjent E; Roques BP; Hanoune J; Maldonado R
Br J Pharmacol; 1998 Dec; 125(7):1567-77. PubMed ID: 9884086
[TBL] [Abstract][Full Text] [Related]
11. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
13. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
14. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential.
Aceto MD; Scates SM; Razdan RK; Martin BR
J Pharmacol Exp Ther; 1998 Nov; 287(2):598-605. PubMed ID: 9808686
[TBL] [Abstract][Full Text] [Related]
15. Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2005 Dec; 1066(1-2):201-5. PubMed ID: 16336946
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome.
Sañudo-Peña MC; Force M; Tsou K; McLemore G; Roberts L; Walker JM
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1121-4. PubMed ID: 11216447
[TBL] [Abstract][Full Text] [Related]
17. Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors.
Tomasini MC; Ferraro L; Bebe BW; Tanganelli S; Cassano T; Cuomo V; Antonelli T
J Neurosci Res; 2002 May; 68(4):449-53. PubMed ID: 11992471
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
19. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.
Rodríguez de Fonseca F; Carrera MR; Navarro M; Koob GF; Weiss F
Science; 1997 Jun; 276(5321):2050-4. PubMed ID: 9197270
[TBL] [Abstract][Full Text] [Related]
20. SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice.
Wilson DM; Varvel SA; Harloe JP; Martin BR; Lichtman AH
Pharmacol Biochem Behav; 2006 Sep; 85(1):105-13. PubMed ID: 16934319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
